FDA Safety Flag
The FDA has identified this substance as one that may present significant safety risks when used in compounding, including concerns about immunogenicity, impurity characterization, and/or insufficient safety information.
Not Approved
This substance is not approved by any major regulatory body for human therapeutic use. All information is derived from preclinical research, limited clinical studies, or off-label contexts.
High Compliance Risk
This substance carries the highest compliance risk for platforms, advertisers, and payment processors. Ad platforms, payment rails, and regulatory bodies actively scrutinize products in this category.
Evidence visual
Melanotan II evidence and risk matrix
advanced researcher fit
Evidence
Tier C
Risk
high
Regulatory
not approved
WADA
unknown
FDA
flagged
Route
subcutaneous
Mixed evidence profile. Useful for comparison, not a standalone protocol decision.
Overview
Melanotan II is a broad melanocortin receptor agonist. Human evidence is dominated by case reports and observational harms rather than controlled therapeutic trials. FDA compounding safety note explicitly cites serious adverse events including melanoma, posterior reversible encephalopathy syndrome, sympathomimetic toxidrome, and priapism. This compound has the highest fraud/overclaim density and compliance risk in the peptide market.
Decision path
Where Melanotan II fits in the research path.
Use the evidence and risk profile first, then compare vendors and run the quiz before turning this compound into a protocol decision.
01
Read evidence
02
Check risk
03
Compare options
04
Build plan
Peptide research path
Decide whether Melanotan II belongs in your plan.
Use the quiz before choosing a compound, vendor, or PDF. It routes by goal, experience, budget, safety flags, and monitoring comfort.
Research Details
Broad melanocortin receptor agonist with pigment and sexual side-effect profiles. Bremelanotide (PT-141) is an active metabolite/derivative in this axis.
subcutaneous
Not a mainstream clinical product; human evidence dominated by case reports.
Pigmentation changes (tanning); sexual arousal effects. NOT a controlled therapeutic product.
Pigmentation changes can occur quickly; adverse events can be acute.
High risk across the board; unlicensed and unapproved.
FDA cites serious adverse events: melanoma, posterior reversible encephalopathy syndrome, sympathomimetic toxidrome, priapism. Immunogenicity/impurity concerns.
Unknown; risk may increase with UV exposure behaviors and stimulant-like exposures.
Cost at a glance
Typical cycle cost
$80.00
Estimated monthly
$53.33
Protocol style
4-6 week burst
Short burst
Estimate confidence
High confidence
Assumes roughly 10 mg–20 mg per cycle, using 2 tracked affiliated listings.
Modeled as a short tanning phase before maintenance, not continuous year-round use.
Known Interactions
Two melanocortin agonists; FDA reports serious adverse events for melanotan II; Rx bremelanotide has cardiovascular contraindications/warnings.
Melanocortin agonist overlap; conservative caution.
Information provided for educational and research reference only. Not medical advice. Not for diagnosing, treating, curing, or preventing disease. Products referenced are labeled Research Use Only (RUO) by vendors; not for human or veterinary use.
Sources and review notes
- Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks - U.S. Food and Drug Administration - accessed 2026-05-15
Used for FDA compounding-risk context and peptide safety flags.
- The Prohibited List - World Anti-Doping Agency - accessed 2026-05-15
Used for athlete-facing WADA risk and peptide-class restrictions.
- Peptide therapeutics: current status and future directions - PubMed / Nature Reviews Drug Discovery - accessed 2026-05-15
Used for broad peptide-therapeutics background and evidence framing.
Personalized peptide routing
Find the right path for Melanotan II.
Take the quiz before choosing a compound, vendor, or PDF. We match your goal, experience, budget, and monitoring comfort to the next best step in the funnel.
- Goal-matched compound and protocol recommendations.
- Budget and sourcing filters before you leave the site.
- PDF unlocks shown after your personalized result.